Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients

CHIH-YANG WANG1-3, PAYAM SHAHI4, JOHN TING WEI HUANG5, NAM NHUT PHAN6,7, ZHENGDA SUN8, YEN-CHANG LIN7, MING-DERG LAI2,3 and ZENA WERB1

1Department of Anatomy, University of California, San Francisco, CA 94143, USA; 2Department of Biochemistry and Molecular Biology; 3Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan 11114, R.O.C.; Departments of 4Bioengineering and Therapeutic Sciences, and 5Oncology, University of California, San Francisco, CA 94143, USA; 6Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh 7000, Vietnam; 7Graduate Institute of Biotechnology, Chinese Culture University, Taipei, Taiwan 11114, R.O.C.; 8Department of Radiology, University of California, San Francisco, CA 94143, USA

Received May 6, 2016; Accepted September 23, 2016

DOI: 10.3892/mco.2016.1094

Abstract. The achaete-scute complex-like (ASCL) family, also referred to as ‘achaete-scute complex homolog’ or ‘achaete-scute family basic helix-loop-helix transcription factor’, is critical for proper development of the nervous system and deregulation of ASCL plays a key role in psychiatric and neurological disorders. The ASCL family consists of five members, namely ASCL1, ASCL2, ASCL3, ASCL4 and ASCL5. The ASCL1 gene serves as a potential oncogene during lung cancer development. There is a correlation between increased ASCL2 expression and colon cancer development. Inhibition of ASCL2 reduced cellular proliferation and tumor growth in xenograft tumor experiments. Although previous studies demonstrated involvement of ASCL1 and ASCL2 in tumor development, little is known on the remaining ASCL family members and their potential effect on tumorigenesis. Therefore, a holistic approach to investigating the expression of ASCL family genes in diverse types of cancer may provide new insights in cancer research. In this study, we utilized a web-based microarray database (Oncomine; www.oncomine.org) to analyze the transcriptional expression of the ASCL family in clinical cancer and normal tissues. Our bioinformatics analysis revealed the potential involvement of multiple ASCL family members during tumor onset and progression in multiple types of cancer. Compared to normal tissue, ASCL1 exhibited a higher expression in cancers of the lung, pancreas, kidney, esophagus and head and neck, whereas ASCL2 exhibited a high expression in cancers of the breast, colon, stomach, lung, head and neck, ovary and testis. ASCL3, however, exhibited a high expression only in breast cancer. Interestingly, ASCL1 expression was downregulated in melanoma and in cancers of the bladder, breast, stomach and colon. ASCL2 exhibited low expression levels in sarcoma, melanoma, brain and prostate cancers. Reduction in the expression of ASCL3 was detected in lymphoma, bladder, cervical, kidney and epithelial cancers. Similarly, ASCL5 exhibited low expression in the majority of brain cancer subtypes, such as glioblastoma and oligodendroglioma. This analysis supports the hypothesis that specific ASCL members may play an important role in cancer development. Collectively, our data suggest that alterations in the expression of ASCL gene family members are correlated with cancer development. Furthermore, ASCL family members were categorized according to cancer subtype. The aim of this report was to provide novel insights to the significance of the ASCL family in various cancers and our findings suggested that the ASCL gene family may be an ideal target for future cancer studies.

Introduction

Cancer is the leading cause of morbidity and mortality worldwide according to the data of the International Agency for Research on Cancer (https://www.iarc.fr/), updated February, 2015. In 2012, there were an estimated 14 million new cancer cases and 8.2 million cancer-related deaths (1). Multiple studies indicate that the most prevalent cancers are lung (1.59 million deaths), liver (745,000 deaths), stomach (723,000 deaths), colorectal (694,000 deaths), breast (521,000 deaths) and esophageal cancer (400,000 deaths) (1). Since aberrations in the transcriptional expression are known to cause cancer, a
primary approach to understanding cancer is to identify oncogenic genes and elucidate their roles in cancer regulation (2).

The achaete-scute complex-like (ASCL) gene family, also referred to as ‘achaete-scute complex homolog’ or ‘achaete-scute family basic helix-loop-helix transcription factor’ and mammalian achaete-scute homologues (MASH), comprises five family members (ASCL1-ASCL5; Table I) (3,4). All ASCL genes encode basic helix-loop-helix transcription factors that control the development of the nervous system (2,3). Given the involvement of ASCL in neuroblast cell fate determination, the ASCL family members are also referred to as proneural genes. The function of the ASCL gene family is highly conserved across all vertebrates; however, ASCL family gene expression and their effect on target cells are not restricted to the nervous system. For example, expression of ASCL family members is detected in progenitor cells during muscle and gut cell differentiation (5-7). These findings emphasize the significance of ASCL genes during organogenesis. However, whether ASCL family members play an integral role in cancer initiation and progression has not been fully elucidated.

ASCL1 is briefly expressed during nervous system development, including olfactory and autonomic neural development (3). ASCL1 is also detected in sympathetic neurons during early embryonic stages in humans (4). In addition to its role during development, ASCL1 overexpression has been associated with human neuroendocrine cancers. However, whether ASCL1 plays a role in the initiation and progression of other cancers remains unclear (8,9).

ASCL2 (HASH2) is expressed by trophoblasts during placental development (10). Recent data suggest that ASCL2 may affect the Wnt signaling pathway. The ASCL2 may form a complex with the Wnt pathway signal transducer β-catenin in order to synergistically activate the expression of downstream target genes (11,12). Moreover, ASCL2 may modulate the plasticity between epithelial and mesenchymal characteristics in colon cancer (13).

Little is known on the function of the remaining ASCL family members. ASCL3 is expressed in adult progenitor cells that mature into acinar- and duct-type cells in murine salivary glands (14). ASCL4 may play a role during skin development and it exhibits a 7-fold higher expression levels in fetal skin compared with adult skin (15). At present, the mechanism and function of ASCL5 are yet to be determined. Although previous studies describe a developmentally significant role for the ASCL gene family, our overall understanding of their function during development and their potential roles during tumorigenesis is incomplete.

Major strives have been made to catalog the mRNA expression profiles of numerous cancers in vast databases. One advantage of these massive resources is to increase our ability to identify potential biomarkers in specific tumors and to characterize their molecular signatures. Since tumor initiation coincides with alterations in normal gene expression, analysis of the differential gene expression in tumor cells may reveal unique tumor biomarkers. Thus, these databases, particularly the Oncomine microarray database (16), were utilized to gain a better understanding of the ASCL family role in the initiation and progression of several tumors, aiming to provide useful insights in prospective research into cancer association with the ASCL gene family.

Materials and methods

**Meta-analysis.** A meta-analysis was used to analyze the mRNA expression of the ASCL family in clinical cancer specimens by following the PRISMA guidelines (17,18) Oncomine (www.oncomine.org), a web-based microarray database, was used to analyze the mRNA expression of ASCL in clinical cancer tissue (19). According to ‘Oncomine Platform Overview Q1 2014,’ the database resource of Oncomine includes upwards of 700 independent datasets with an estimated 90,000 microarray trials. Oncomine has standardized and organized the datasets of public cancer microarray data into different cancer type and subtypes (16,20).

**ASCL gene expression.** ASCL gene (ASCL1-5) expression in 20 cancer types was investigated. Detailed information on ASCL genes, such as tissue of origin, comparing mRNA expression with matched normal tissue types, was displayed in groups. The gene summary view on Oncomine was presented throughout the analysis with an alteration in color, reflecting the degree of expression. The expression coloration represents a gene with highest ranking in a particular type of cancer based on the threshold analysis (Fig. 1).

**Statistical analysis.** The cancer vs. normal filter that only displayed datasets investigating ASCL gene mRNA expression in the same tissue of origin was selected. To be included in the study, all the data had to satisfy the threshold with a P-value of <0.01, a fold change of >1.5 and a gene rank percentile of <10%. Statistical analyses were performed using the Oncomine default algorithms, such as P-values, two-tailed Student's t-test, and multiple testing corrections.

**Results and Discussion**

**Analysis of ASCL expression in various tumors.** Several studies have identified potential roles for ASCL family members in cancer development; however, our overall understanding of ASCL family member function during tumor initiation and progression is incomplete. To investigate a potential alteration in ASCL family gene expression in different types of cancer, we accessed the web-based Oncomine microarray database to analyze 20 different types of cancer. Cancer tissue was compared with normal tissue (control) and thresholds were set to screen suitable datasets from the Oncomine database. To include suitable datasets for further analysis, the gene expression in cancer cells compared with that of normal tissue had to fulfill the following threshold criteria: Fold change >1.5, P<0.01 and gene rank percentile <10% (Fig. 1). Our analysis demonstrated alterations in ASCL gene family expression in multiple cancer types, which may provide useful information for future studies investigating the role of ASCL genes in tumorigenesis.

**ASCL1.** The proneural transcriptional factor ASCL1/MASH1 is essential for proper nervous system development (21). In the cerebrum, ASCL1 controls the primitive as well as the late phases of neurogenesis, with the division of radial glia progenitors and the radial migration of post-mitotic neurons (22,23). ASCL1 controls the expression of numerous target genes that are involved in cell cycle progression and cytoskeletal
reorganization associated with neuronal cell migration (6, 7).
Recently, a potential oncogenic role for ASCL1 in lung cancer has been reported (23); however, the role of ASCL1 in cancer remains unclear. Our analysis indicated that ASCL1 is significantly overexpressed in the majority of cancer types, such as cancers of the brain, lung, head and neck, prostate, pancreas, kidney, esophagus, leukemia, lymphoma and sarcoma (Fig. 1). ASCL1 also ranked in the top 1% of overexpressed genes in leukemia, brain and lung cancer. Importantly, our analysis indicated that ASCL1 is overexpressed in the majority of brain cancers, such as glioblastoma, oligodendroglioma, anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma. Compared with normal tissue, ASCL1 exhibited a higher expression in brain tumor tissues (P-values of 0.004-2.50E-21), and the ASCL1 gene ranked 1-7% in our meta-analysis results (Table II). We found that, in various lung cancers, such as small-cell lung carcinoma and carcinoid tumors, ASCL1 was significantly overexpressed (P-values of 0.002-3.53E-13) and the gene ranked in the top 1-8% relative to the control. In addition to brain tumors, ASCL1 was also highly expressed in acute adult T-cell leukemia/lymphoma, with the gene ranking in the top 1%, a 3.76-fold change, and a P=3.43E-5. These data indicated that ASCL1 expression varied in different types of leukemia. We also observed that ASCL1 was highly expressed in leiomyosarcoma (3.55-fold change, P=6.13E-4 and gene ranking in the top 7%), prostate carcinoma (3.21-fold change, P=0.001 and gene ranking in the top 1%), pancreatic adenocarcinoma (3.22-fold change, P=0.002 and gene ranking in the top 6%), renal oncocytoma (5.16-fold change, P=0.002 and gene ranking in the top 8%) and Barrett’s esophagus (1.95-fold change, P=0.002 and gene ranking in the top 9%) (Table II).

In contrast to brain cancer and lymphomas, other cancers exhibited a reduction in ASCL1 expression. Gastric cancer and melanoma were among the top 1% of tumors that exhibited ASCL downregulation. The reduction in the ASCL1 transcript level suggested a tumor suppressor role, since tumor suppressor genes tend to exhibit a low or reduced expression in tumor tissue compared with normal tissue. Our analysis indicated lower ASCL1 expression in gastric, bladder and lung cancers. Evidence of this trend is also supported by a previous study that specifically evaluated a tumor suppressor gene in breast cancer datasets from the Oncomine database, which revealed a significant downregulation and low expression of the tumor suppressor gene ADAMTS1 in breast carcinomas when compared with normal tissue (24). Another similar study on the SIRT3 tumor suppressor gene also revealed lower expression in various tumor types (25). Given the pattern of downregulation, we hypothesized that ASCL1 may also play a tumor suppressor role in a subset of tissues. ASCL1 expression was considerably downregulated in lymphoma (diffuse large B-cell lymphoma, primary effusion lymphoma and mantle cell

| Official symbol | Alias | Biological function | (Refs.) |
|-----------------|-------|---------------------|---------|
| ASCL1           | ASH1, HASH1, MASH1, bHLHa46 | Regulation of transcription from RNA polymerase II promoter | (37) |
|                 |       | Cerebral cortex GABAergic interneuron differentiation | (38) |
|                 |       | Sympathetic nervous system development | (39) |
|                 |       | Negative regulation of apoptotic process | (40) |
|                 |       | Noradrenergic neuron fate commitment | (41) |
|                 |       | Lung epithelial cell differentiation | (42) |
|                 |       | Notch signaling pathway | (43) |
|                 |       | Response to retinoic acid | (37) |
|                 |       | Neurogenesis | (44) |
| ASCL2           | ASH2, HASH2, MASH2, bHLHa45 | Regulation of transcription from RNA polymerase II promoter | (45, 46) |
|                 |       | Spongiotrophoblast differentiation | (47) |
|                 |       | In utero embryonic development | (10) |
|                 |       | Sequence-specific DNA binding | (45) |
|                 |       | Somatic stem cell maintenance | (9) |
|                 |       | Placenta development | (48) |
| ASCL3           | SGN1, HASH3, bHLHa42 | RNA polymerase II regulatory region sequence-specific DNA binding | (49) |
|                 |       | Regulation of transcription from RNA polymerase II promoter | (49) |
|                 |       | Transcription factor complex | (49) |
| ASCL4           | HASH4, bHLHa44 | Regulation of transcription from RNA polymerase II promoter | (15) |
|                 |       | Skin development | (15) |
| ASCL5           | bHLHa47 | Regulation of transcription, DNA-template | (33) |

ASCL,achaete-scute complex-like; bHLH, basic helix-loop-helix.
lymphoma). The reduction in ASCL1 expression ranged from -1.61- to -2.08-fold change, with P-values of 9.25E-4-1.15E-6 and the gene ranking in the top 3-10%. Our bioinformatics analyses of gastric cancer revealed that ASCL1 exhibited a lower expression in the majority of gastric cancer subtypes, namely gastric mixed adenocarcinoma, gastrointestinal stromal tumors and gastric intestinal-type adenocarcinoma. The ASCL1 expression ranged from -1.60- to -3.64-fold downregulation, with P-values of 0.002-1.06E-6 and the gene ranking in the top 1-8%. ASCL1 exhibited a lower expression in most types of melanoma, namely cutaneous melanoma, non-neoplastic nevus, benign melanocytic skin nevus and monoclonal gammopathy of undetermined significance. The ASCL1 transcript expression ranged from -1.64- to -3.22-fold downregulation, with P-values of 0.003-2.27E-5 and the gene ranking in the top 1-10%. ASCL1 also exhibited a lower expression in bladder cancer (-1.77-fold change, P=2.36E-6 and gene ranking in the top 6%), invasive ductal breast carcinoma (-1.59-fold change, P=5.03E-6 and gene ranking in the top 3%) and colon cancer (-3.58-fold change, P=9.57E-6 and gene ranking in the top 7%) (Table II). These analyses suggest that the effect of ASCL1 downregulation on transcript expression may be an equally important alteration as increased expression in cancer biology. Interestingly, ASCL1 was found to be both up- and downregulated in brain tumors compared with normal tissue. The conflicting expression profiles of ASCL1 in the same type of cancer may be due to the wide-ranging categories for each of the cancer subtypes (Table II). This discrepancy may be a sample size issue arising from the original publications' reported data including a low number of samples from these tumor types. Collectively, our data suggest that alterations in ASCL1 expression may adversely affect tissue homeostasis, which may result in tumorigenesis.

**ASCL2.** ASCL2 is a basic helix-loop-helix transcription factor that is expressed in neuronal precursors (26). ASCL2 is a target of the Wnt signaling pathway and previous studies indicated that ASCL2 may regulate LGR5 in intestinal stem cells in response to Wnt signaling (9,27). Moreover, ASCL2 is involved in T-helper cell (TH) 1 and TH17 differentiation (28). ASCL2 is strongly expressed in colon cancer tissues and cell lines (HT-29 and LS174T cells). Selective blockade of
Table II. Achaete-scute complex-like (ASCL) 1 expression in cancer.

| Gene               | Cancer                      | Subtype                       | Case no. | Change expression | P-value (cancer/normal) | t-test (cancer/normal) | Fold change (cancer/normal) | % Gene ranking | Database reference |
|--------------------|-----------------------------|-------------------------------|----------|-------------------|-------------------------|------------------------|----------------------------|----------------|-------------------|
| ASCL1              | Brain                       | Oligodendroglioma             | 180      | ↑                  | 2.50E-21                | 13.45                  | 4.40                       | 5 (top 1%)     | (51)              |
|                    |                             | Oligodendroglioma             | 54       | ↓                  | 4.68E-4                 | -5.78                  | -1.81                      | 316 (top 3%)   | (52)              |
|                    |                             | Glioblastoma                  | 180      | ↑                  | 4.68E-11                | 7.83                   | 3.64                       | 1,181 (top 7%) | (51)              |
|                    |                             | Glioblastoma                  | 38       | ↓                  | 3.87E-8                 | -7.30                  | -1.63                      | 61 (top 1%)    | (53)              |
|                    |                             | Glioblastoma                  | 101      | ↓                  | 6.47E-8                 | -7.81                  | -5.48                      | 1,186 (top 7%) | (54)              |
|                    |                             | Anaplastic astrocytoma        | 180      | ↑                  | 1.45E-10                | 9.58                   | 5.30                       | 86 (top 1%)    | (51)              |
|                    |                             | Glioblastoma                  | 84       | ↑                  | 1.06E-11                | 10.48                  | 3.38                       | 244 (top 2%)   | (55)              |
|                    |                             | Anaplastic oligodendroglioma  | 33       | ↑                  | 1.01E-9                 | 8.89                   | 5.22                       | 71 (top 1%)    | (56)              |
|                    |                             | Brain glioblastoma            | 557      | ↑                  | 1.06E-9                 | 12.86                  | 4.32                       | 546 (top 5%)   | (57)              |
|                    |                             | Anaplastic oligoastrocytoma   | 54       | ↑                  | 0.001                   | 4.52                   | 2.99                       | 283 (top 2%)   | (52)              |
|                    |                             | Anaplastic oligodendroglioma  | 54       | ↑                  | 0.004                   | 4.37                   | 1.57                       | 501 (top 4%)   | (52)              |
|                    |                             | Oligoastrocytoma              | 38       | ↓                  | 3.60E-4                 | -12.58                 | -1.90                      | 30 (top 1%)    | (53)              |
|                    |                             | Astrocytoma                   | 42       | ↓                  | 3.96E-4                 | -5.16                  | -1.51                      | 184 (top 3%)   | (58)              |
| Lung               |                             | Small-cell lung carcinoma     | 203      | ↑                  | 3.53E-13                | 17.89                  | 576.45                     | 2 (top 1%)    | (59)              |
|                    |                             | Lung carcinoid tumor          | 203      | ↑                  | 0.002                   | 3.15                   | 5.56                       | 641 (top 8%)   | (59)              |
|                    |                             | Small-cell lung carcinoma     | 73       | ↑                  | 1.43E-5                 | 8.49                   | 18.57                      | 20 (top 1%)    | (60)              |
|                    | Leukemia                    | Acute adult T-cell leukemia/lymphoma | 47 | ↑ | 3.43E-5 | 4.75 | 3.76 | 99 (top 1%) | (61) |
|                    | Lymphoma                    | Diffuse large B-cell lymphoma | 336      | ↓                  | 1.15E-6                 | -5.28                  | -1.61                      | 180 (top 3%)   | (63)              |
|                    | Primary effusion lymphoma   | 336                            | ↓         |                    | 9.25E-4                 | -4.17                  | -2.08                      | 792 (top 10%)  | (63)              |
|                    | Mantle cell lymphoma        | 336                            | ↓         |                    | 9.25E-4                 | -4.18                  | -1.83                      | 223 (top 3%)   | (63)              |
| Head and neck      | Salivary gland adenoid cystic carcinoma | 22 | ↑ | 4.89E-4 | 6.19 | 62.22 | 674 (top 8%) | (64) |
| Sarcoma            | Leiomyosarcoma              | 54                             | ↑         |                    | 6.13E-4                 | 3.80                   | 3.55                       | 777 (top 7%)   | (65)              |
|                    | Gastrointestinal stromal tumor | 90 | ↓ | 9.50E-5 | -4.67 | -1.57 | 1,356 (top 8%) | (66) |
| Prostate           | Prostate carcinoma          | 35                             | ↑         |                    | 0.001                   | 4.99                   | 3.21                       | 179 (top 3%)   | (67)              |
|                    | Prostate carcinoma          | 122                            | ↓         |                    | 4.19E-5                 | -4.25                  | -1.60                      | 1,743 (top 10%)| (68)              |
| Pancreas           | Pancreatic adenocarcinoma   | 36                             | ↑         |                    | 0.002                   | 4.43                   | 3.22                       | 760 (top 6%)   | (69)              |
| Kidney             | Renal oncocytoma            | 67                             | ↑         |                    | 0.002                   | 4.17                   | 5.16                       | 1,540 (top 8%) | (70)              |
| Esophagus          | Barrett’s esophagus         | 48                             | ↑         |                    | 0.002                   | 3.09                   | 1.95                       | 1,283 (top 9%) | (71)              |
| Gastric            | Gastric mixed adenocarcinoma| 90                             | ↓         |                    | 1.06E-6                 | -6.44                  | -1.63                      | 133 (top 1%)   | (66)              |
|                    | Gastric intestinal-type adenocarcinoma | 69 | ↓ | 1.29E-6 | -5.29 | -3.64 | 357 (top 2%) | (72) |
|                    | Gastric cancer              | 27                             | ↓         |                    | 0.002                   | -3.18                  | -2.68                      | 583 (top 3%)   | (73)              |
|                    | Gastric cancer              | 160                            | ↓         |                    | 0.004                   | -2.71                  | -1.60                      | 1,365 (top 8%) | (74)              |
ASCL2 disrupts tumor cell proliferation and migration in tumor xenograft models (10,29,30), a result consistent with our bioinformatics analysis (Fig. 1). This is particularly true in colon cancer tissues compared with normal tissues; however, whether ASCL2 plays a role in initiation and progression of other tumor types remains unclear.

ASCL2 expression was altered in 8 of 21 investigated cancers and was commonly observed in colorectal, gastric, breast, ovarian, testicular, lung and head and neck cancers, as well as lymphoma (Fig. 1). However, based on our bioinformatics analysis, our results were strikingly different. Downregulation of ASCL2 was only observed in the top 5% and 9% of underexpressed genes in melanoma, and brain and gastric cancers, respectively (Fig. 1).

Our analysis revealed that ASCL2 expression is significantly upregulated in various breast cancer subtypes, such as invasive ductal, invasive lobular and medullary breast carcinoma, with P-values of 0.009-4.39E-72, gene ranking 2-10% and a fold change of 1.66-14.9 compared with normal tissues (Table III). In colorectal tumors, such as adenocarcinoma of the colon, rectum, cecum or rectosigmoid region, colonic adenoma, rectal adenoma, colon adenoma epithelia and colon carcinoma epithelia, ASCL2 also exhibited significant upregulation compared with normal tissues, with P-values of 3.60E-7-8.24E-52, gene ranking 1-9% and a fold change of 5.64-31.35 (Table III).

In gastric cancers, such as diffuse gastric adenocarcinoma, gastric intestinal-type adenocarcinoma and gastric mixed adenocarcinoma, ASCL2 exhibited significant upregulation compared with normal tissues, with P-values of 6.30E-4-1.74E-6, gene ranking 1-5% and a fold change of 2.35-4.45. Additionally, we found that ASCL2 is highly expressed in squamous cell lung carcinoma (1.84-fold change, P=7.81E-8 and gene ranking in the top 9%), nodular lymphocyte-predominant Hodgkin’s lymphoma (2.65-fold change, P=7.61E-5 and gene ranking in the top 5%), nasopharyngeal carcinoma (1.56-fold change, P=5.08E-4 and gene ranking in the top 10%), ovarian endometrioid adenocarcinoma (1.76-fold change, P=0.001 and gene ranking in the top 3%); testicular seminoma (3.21-fold change, P=0.007 and gene ranking in the top 6%) (Table III).

Of note, lower ASCL2 gene expression levels were found in certain cancer subtypes, such as brain and gastric cancer, and melanoma. These subtypes included oligodendroglioma (-1.73-fold change, P=4.42E-4 and gene ranking in the top 9%), gastrointestinal stromal tumors (-2.59-fold change, P=4.59E-4 and gene ranking in the top 9%), and cutaneous melanoma (-6.74-fold change, P=6.22E-4 and gene ranking in the top 5%) (Table III). Thus, ASCL2 exhibited increased mRNA expression in some cancer tissues and decreased expression in others. Overall, our analysis indicated that ASCL2 was ranked in the top 10% of genes involved in the regulation of breast, colorectal, lung, gastric, head-neck, ovarian and testicular cancers and lymphoma, whereas in brain cancer and melanoma it exhibited significant downregulation compared with normal tissue (Table III). These findings indicate that cell context-specific alterations in ASCL2 expression may play a critical role in cancer biology.

ASCL3. ASCL3 (Sgn1) belongs to the MASH gene family of transcription factors that has been associated with cell fate
Table III. Achaete-scute complex-like (ASCL) 2 expression in cancer.

| Gene                  | Cancer                                      | Subtype                                      | Case no. | Change expression | P-value (cancer/normal) | t-test (cancer/normal) | Fold change (cancer/normal) | % Gene ranking | Database reference |
|-----------------------|---------------------------------------------|----------------------------------------------|----------|-------------------|-------------------------|------------------------|-----------------------------|----------------|-------------------|
| ASCL2                 | Breast                                      | Invasive ductal breast carcinoma             | 2136     | ↑                 | 4.39E-72                | 23.54                  | 2.14                        | 582 (top 4%)   | (81)              |
|                       |                                             | Invasive lobular breast carcinoma            | 2136     | ↑                 | 1.42E-26                | 12.34                  | 2.31                        | 1,080 (top 6%) | (81)              |
|                       |                                             | Invasive ductal and invasive lobular breast carcinoma | 2136 | ↑                 | 4.26E-16                | 9.38                   | 2.05                        | 1,794 (top 10%) | (81)              |
|                       |                                             | Medullary breast carcinoma                   | 2136     | ↑                 | 5.67E-12                | 9.87                   | 2.84                        | 449 (top 3%)   | (81)              |
|                       |                                             | Breast carcinoma                             | 2136     | ↑                 | 1.88E-4                 | 4.60                   | 1.67                        | 1,375 (top 8%) | (81)              |
|                       |                                             | Invasive breast carcinoma stroma             | 59       | ↑                 | 1.49E-14                | 11.34                  | 3.91                        | 1,068 (top 6%) | (82)              |
|                       |                                             | Ductal breast carcinoma in situ              | 63       | ↑                 | 0.009                   | 4.18                   | 14.91                       | 289 (top 2%)   | (83)              |
|                       | Colorectal                                  | Rectal adenocarcinoma                        | 130      | ↑                 | 8.24E-52                | 26.18                  | 9.71                        | 10 (top 1%)    | (84)              |
|                       |                                              | Colon adenocarcinoma                         | 237      | ↑                 | 3.20E-27                | 15.78                  | 6.53                        | 125 (top 1%)   | (98)              |
|                       |                                              | Rectal adenocarcinoma                        | 237      | ↑                 | 3.36E-27                | 16.38                  | 8.77                        | 66 (top 1%)    | (98)              |
|                       |                                              | Cecum adenocarcinoma                         | 237      | ↑                 | 1.97E-12                | 10.84                  | 6.28                        | 396 (top 2%)   | (98)              |
|                       |                                              | Rectosigmoid adenocarcinoma                  | 237      | ↑                 | 2.31E-8                 | 18.07                  | 6.50                        | 206 (top 2%)   | (98)              |
|                       |                                              | Colon adenocarcinoma                         | 105      | ↑                 | 1.36E-26                | 23.35                  | 8.96                        | 2 (top 1%)     | (85)              |
|                       |                                              | Cecum adenocarcinoma                         | 105      | ↑                 | 8.03E-8                 | 8.60                   | 7.15                        | 274 (top 2%)   | (85)              |
|                       |                                              | Rectal adenocarcinoma                        | 105      | ↑                 | 1.02E-6                 | 12.69                  | 6.64                        | 50 (top 1%)    | (85)              |
|                       |                                              | Rectosigmoid adenocarcinoma                  | 105      | ↑                 | 1.87E-4                 | 5.47                   | 6.95                        | 1,632 (top 9%) | (85)              |
|                       |                                              | Colorectal carcinoma                         | 82       | ↑                 | 3.55E-19                | 15.43                  | 24.81                       | 46 (top 1%)    | (86)              |
|                       |                                              | Colorectal adenocarcinoma                    | 105      | ↑                 | 2.63E-18                | 12.56                  | 6.13                        | 62 (top %)     | (87)              |
|                       |                                              | Colorectal carcinoma                         | 105      | ↑                 | 1.72E-13                | 9.40                   | 5.64                        | 100 (top 1%)   | (87)              |
|                       |                                              | Colon adenoma                                | 64       | ↑                 | 5.60E-18                | 15.27                  | 8.94                        | 101 (top 1%)   | (77)              |
|                       |                                              | Rectal adenoma                               | 64       | ↑                 | 3.80E-5                 | 7.84                   | 17.43                       | 1,580 (top 9%) | (77)              |
|                       |                                              | Colon adenoma                                | 40       | ↑                 | 1.80E-11                | 21.19                  | 31.35                       | 17 (top 1%)    | (87)              |
|                       |                                              | Colon carcinoma                              | 40       | ↑                 | 1.05E-10                | 20.53                  | 24.23                       | 162 (top 1%)   | (87)              |
|                       |                                              | Colon adenoma epithelia                      | 40       | ↑                 | 5.68E-8                 | 10.74                  | 14.14                       | 233 (top 2%)   | (87)              |
|                       |                                              | Colon carcinoma epithelia                    | 40       | ↑                 | 3.60E-7                 | 10.42                  | 10.79                       | 914 (top 5%)   | (87)              |
|                       | Lung                                         | Squamous cell lung carcinoma                 | 156      | ↑                 | 7.81E-8                 | 6.48                   | 1.84                        | 1,660 (top 9%) | (88)              |
|                       |                                              | Squamous cell lung carcinoma                 | 203      | ↑                 | 0.004                   | 2.79                   | 3.63                        | 639 (top 8%)   | (59)              |
|                       | Gastric                                      | Diffuse gastric adenocarcinoma               | 90       | ↑                 | 1.74E-6                 | 5.35                   | 3.40                        | 348 (top 2%)   | (66)              |
|                       |                                              | Gastric intestinal-type adenocarcinoma       | 90       | ↑                 | 3.01E-6                 | 5.68                   | 4.17                        | 131 (top 1%)   | (66)              |
|                       |                                              | Gastric mixed adenocarcinoma                 | 90       | ↑                 | 6.30E-4                 | 4.35                   | 4.45                        | 923 (top 5%)   | (66)              |
|                       |                                              | Gastric cancer                               | 160      | ↑                 | 9.27E-6                 | 4.43                   | 2.35                        | 400 (top 3%)   | (74)              |
|                       |                                              | Gastrointestinal stromal tumor              | 90       | ↓                 | 4.59E-4                 | -4.91                  | -2.59                       | 7,733 (top 9%) | (66)              |
determination and contributes to the maintenance of the adult salivary gland homeostasis (11,31). Our database analysis indicated that ASCL3 was highly expressed in invasive ductal breast carcinoma (2.26-fold change, P=0.002 and gene ranking in the top 2%) compared with normal tissues (Table IV). Of the 21 analyzed tumor types, 5 exhibited a correlation with downregulation of ASCL3 (Table IV).

Analysis of various renal tumor subtypes indicated that ASCL3 exhibited a lower expression in renal oncocytoma with a fold change of -1.60, P=5.15E-16 and gene ranking in the top 3%. ASCL3 expression is downregulated in cervical cancer with a fold change of -1.65, P=1.24E-9 and gene ranking in the top 1%. In superficial bladder cancer, we found that ASCL3 also exhibited a lower expression, with a fold change of -1.63, P=1.16E-7 and the gene ranking in the top 3%. In anaplastic large-cell lymphoma, ASCL3 exhibited lower expression, with a fold change of -1.96, P=1.58E-5 and the gene ranking in the top 8%. Melanomas and basal cell skin carcinoma (also referred to as basalioma, the most common malignant skin tumor), exhibited ASCL3 downregulation with a fold change of -1.80, P=0.007 and the gene ranking in the top 10% (Table IV). Thus, ASCL3 ranked in the top 2% of genes exhibiting upregulation in breast cancer, while in renal, cervical and bladder cancer, lymphoma and melanoma, ASCL3 displayed significant downregulation compared with normal tissues (Table IV). These findings indicated that ASCL3 may be differentially expressed in specific types of cancer and that further investigation is required to determine the mechanisms underlying the involvement of ASCL3 in tumorigenesis.

**ASCL4.** ASCL4 (HASH4, bHLHα44) expression is associated with skin development. ASCL4 exhibited a 7-fold higher expression in fetal skin compared with adult skin (12). The role of ASCL4 in cellular function remains elusive. Therefore, comparative genomic sequencing did not reveal any function for this gene (32). ASCL4 expression did not satisfy the selection criteria of the present study; therefore, it was not selected for further investigation.

**ASCL5.** We were unable to obtain any data regarding ASCL5 based on the literature search through the PubMed database. Analysis of the Gene Ontology database indicated that ASCL5 may be involved in the regulation of DNA-templated transcription (33). Our bioinformatics analysis suggested that ASCL5 was upregulated in lung cancer with a fold change of 1.96-3.71, P-values of 0.002-0.003 and the gene ranking 5-9%. However, ASCL5 was downregulated in the majority of types of brain tumors, such as glioblastoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma and oligodendroglioma, with a fold change of -3.10 to -5.50, P-values of 0.002-5.25E-12 and the gene ranking 1-6% (Table V). To the best of our knowledge, our bioinformatics analysis is the first report to provide any information regarding the potential role of ASCL5 in tumorigenesis.

**ASCL family in clinical application.** In this report, we presented an *in silico* analysis of the ASCL gene family and investigated the potential involvement of ASCL genes in various cancers. Our meta-analysis approach provided a conspectus of the clinical data related to the ASCL gene.
family and suggested that alterations in the ASCL genes may result in development of various tumors. Moreover, our analysis utilized the integration and validation of numerous microarray datasets, thereby allowing the use of an ASCL gene with its correlated cancers and its subtypes as future biomarkers for future cancer studies.

It was previously indicated that ASCL1 functions as an oncogene in lung cancer (23). Recent findings also demonstrated that ASCL1 is a marker for small-cell lung carcinomas (23,34). These data are consistent with our bioinformatics analyses (Fig. 1). Strikingly, ASCL2 expression analysis indicated increased mRNA expression in some cancer tissues and decreased expression in others. ASCL2 is in the top 10% of genes exhibiting overexpression in breast, colorectal, lung, gastric, head-neck, ovarian and testicular cancers, as well as lymphoma. However, brain tumor and melanoma subtypes exhibited significant reductions in the expression of ASCL2 when compared with normal tissues (Table III). Of note, ASCL3 expression displayed a wide range of mRNA levels in various cancers. ASCL3 was in the top 2% of overexpressed genes in breast cancer. Conversely, in lymphomas, melanomas,

### Table IV. Achaete-scute complex-like (ASCL) 3 expression in cancer.

| Gene   | Cancer                        | Subtype                     | Case no. | Change expression | P-value (cancer/normal) | t-test (cancer/normal) | Fold change (cancer/normal) | % Gene ranking | Database reference |
|--------|-------------------------------|-----------------------------|----------|-------------------|-------------------------|------------------------|-------------------------------|----------------|-------------------|
| ASCL3  | Breast                        | Invasive ductal breast carcinoma | 30 | ↑                 | 0.002                   | 3.33                   | 2.26                          | 220 (top 2%) | (94)              |
|        | Kidney                        | Renal oncocytoma            | 92       | ↓                 | 5.15E-16                | -14.47                 | -1.60                         | 340 (top 3%) | (95)              |
|        | Clear cell renal cell carcinoma | 20             | ↓                 | 2.48E-4                | -4.66                   | -3.08                         | 1,143 (top 10%) | (95)             |
|        | Cervical                      | Cervical cancer             | 84       | ↓                 | 1.24E-9                 | -8.49                   | -1.65                         | 96 (top 1%)  | (96)              |
|        | Bladder                       | Superficial bladder cancer  | 60       | ↓                 | 1.16E-7                 | -6.62                   | -1.63                         | 274 (top 3%) | (75)              |
|        | Lymphoma                      | Anaplastic large-cell lymphoma | 60   | ↓                 | 1.58E-5                 | -8.87                   | -1.96                         | 1,547 (top 8%) | (97)              |
|        | Melanoma                      | Skin basal cell carcinoma   | 87       | ↓                 | 0.007                   | -2.74                   | -1.80                         | 1,915 (top 10%) | (80)              |

### Table V. Achaete-scute complex-like (ASCL) 5 expression in cancer.

| Gene   | Cancer                        | Subtype                     | Case no. | Change expression | P-value (cancer/normal) | t-test (cancer/normal) | Fold change (cancer/normal) | % Gene ranking | Database reference |
|--------|-------------------------------|-----------------------------|----------|-------------------|-------------------------|------------------------|-------------------------------|----------------|-------------------|
| ASCL5  | Lung                          | Small-cell lung carcinoma   | 73       | ↑                 | 0.003                   | 4.91                   | 3.71                          | 442 (top 5%) | (60)              |
|        | Squamous cell lung carcinoma  | 73             | ↑                 | 0.002                   | 3.26                   | 1.96                          | 911 (top 9%)  | (60)              |
|        | Brain                         | Glioblastoma                | 54       | ↓                 | 5.25E-12                | -11.49                 | -3.10                         | 141 (top 1%) | (52)              |
|        | Anaplastic oligoastrocytoma   | 54             | ↓                 | 1.57E-4                 | -7.74                   | -3.79                         | 322 (top 3%) | (52)              |
|        | Anaplastic oligodendroglioma  | 54             | ↓                 | 7.70E-4                 | -13.99                 | -5.50                         | 480 (top 4%) | (52)              |
|        | Oligodendroglioma             | 54             | ↓                 | 0.002                   | -5.74                   | -4.24                         | 878 (top 6%) | (52)              |
renal, cervical and bladder cancers, ASCL3 expression was significantly reduced compared with that in normal tissues (Table IV). Expression analysis of ASCL5 suggested a correlation between elevated ASCL5 expression and lung cancer development. ASCL5 was one of highly expressed genes, ranking 5-9% in lung cancer. Interestingly, ASCL5 was downregulated in most types of brain tumors, such as glioblastoma, anaplastic oligoastrocytoma and anaplastic oligodendroglioma. The decrease in fold change ranged from -3.10 to -5.50, the P-values ranged from 0.002 to 5.25E-12, with the gene ranking 1-6% (Table V). Intriguingly, ASCL members exhibited increased expression in some cancer tissues and decreased expression in others. This is particularly apparent for ASCL2, ASCL3 and ASCL5 that displayed mRNA expression changes (either up- or downregulated in specific cancers). According to these data, both the up- and downregulation of ASCL genes may play an important role in tumor development. The emerging view of the unique developmental niche of ASCL members in early progenitors of diverse neural lineages suggests a potentially critical role in injury response, wound healing and tumorigenesis. However, a limited number of studies to date suggest that these ASCL members may contribute significantly to cancer development. The available data collectively suggest that alterations in the expression of ASCL genes may affect cellular behavior, such as cell proliferation, thereby initiating tumor development. The present study demonstrated that ASCL members may be involved in tumor development and introduces ASCL genes as potential candidates for future prognostic and therapeutic targets.

Acknowledgements

Computational analyses and data mining were performed using the system provided by the Bioinformatics Core at the National Cheng Kung University, supported by the National Science Council, Taiwan. We would also like to thank the Ministry of Science and Technology for the grants MOST103-2325-B006-012 (to MDL) and 104-2917-I-006-002 (to CYW) and the National Cancer Institute (USA) for the R01 CA180039 grant (to ZW).

References

1. Forman D, Ferlay J, Stewart B and Wild C: The global and regional burden of cancer. World cancer report 64-185, 2014.
2. Haman D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
3. Guillemot F, Lo LC, Johnson JE, Auerbach A, Anderson DJ and Joyner AL: Mammalian achaete-scute homolog-1 is required for the early development of olfactory and autonomic neurons. Cell 73: 467-476, 1993.
4. Gesblom C, Grynfelt A, Ora I, Ortolf E, Larsson C, Axelson H, Sandstedt B, Cserjesi P, Olson EN and Pálhalmi S: The basic helix-loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblasomas. Lab Invest 79: 67-79, 1999.
5. Mizuguchi R, Kriks S, Cordes R, Gossler A, Ma QF and Brunet JF: ASCL1 and GSIH1/2 control inhibitory and excitatory cell fate in spinal sensory interneurons. Nat Neurosci 9: 770-778, 2006.
6. Patten A, Simplicio N, van Doorninck JH, Goridis C, Guillemot F and Brunet JF: ASCL1/MASH1 is required for the development of central serotoninergic neurons. Nat Neurosci 7: 589-595, 2004.
7. Ge WH, He F, Kim KJ, Blanchi B, Coskun V, Nguyen L, Wu X, Zhao J, Heng Ji, Martinovich K, et al: Coupling of cell migration with neurogenesis by proneural bHLH factors. Proc Natl Acad Sci USA 103: 1319-1324, 2006.
8. Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB and Ball DW: An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386: 852-855, 1997.
9. Tani Y, Pan Q, Shang Y, Zhu R, Xu J, Liu Y, Zhong X, Li S, He Y, Chen L, et al: MicroRNA-200 (miR-200) cluster regulation by achaete-scute-like2 (ASCL2): Impact on the epithelial-mesenchymal transition in colon cancer cells. J Biol Chem 289: 36101-36115, 2014.
10. Guilleminot F, Agile P, Auerbach A, Rossant J and Joyner AL: Essential role of MASH-2 in extraembryonic development. Cell 75: 463-476, 1993.
11. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Neuron 69: 1069-1084, 2011.
12. Ruigl-Stahl A, Elliott ME and Ovitt CE: Ascl3 marks adult progenitor cells of the mouse salivary gland. Stem Cell Res 8: 379-387, 2012.
13. Jonsson B, Björntorp Mark E, Brantsing C, Brandner MV, Lindahl A and Asp J: HASH4, a novel human achaete-scute homologue found in fetal skin. Genomics 37: S31-S37, 2004.
14. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180, 2007.
15. W Duel JA, Downs TM, Cetrar JP and Ricca WA: Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS One 8: e55414, 2013.
16. Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339: b2535, 2009.
17. Rhodes DR and Chinnanai AM: Integrative analysis of the oncogenic transcription program in glioblastoma: 859-866, 2004.
18. Rhodes DR, Yu JJ, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnanai AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6, 2004.
19. Casarosa S, Fode C and Guillemot F: MASH1 regulates neurogenesis in the ventral telencephalon. Development 126: 525-534, 1999.
20. Pacary E, Heng JL, Azzarelli R, Riou P, Castro D, Lebel-Poller M, Parras C, Bell DM, Ridley AJ, Parsons M and Guillemot F: Proneural transcription factors regulate different steps of cortical neuron migration through Rnd-mediated inhibition of RhoA signaling. Neuro 69: 1069-1084, 2011.
21. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoyo PD, Lee V, Tan C, Sullivan JP, Larsen JE, et al: ASCL1 is a genome oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA 111: 14788-14793, 2014.
22. Martino-Echarri E, Fernandez-Rodriguez R, Rodriguez-Baena FJ, Barrientos-Duran A, Torres-Collado AX, Plaza-Calonge Mdel C, Amador-Cubero S, Cortes J, Reynolds LE, Hidivila-Dilke KM, et al: Contribution of ADAMTS1 to a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. Int J Cancer 133: 2315-2324, 2013.
23. Blak HS, Patel K, Muldown-Jacobs K, Bish KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, et al: SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 45-52, 2010.
24. Johnson JE, Birren SJ and Andersson DJ: Two rat homologues of drosophila achaete-scute specifically expressed in neuronal precursors. Nature 346: 858-861, 1990.
Gene expression profiling reveals molecularly specified human neural progenitor cells derived from the undifferentiated forebrain. Dev Biol 320: 72-78, 2008.

Amid C, Bahar A, Mujica A, Sampson N, Brikar SE, Winterpacht A, Zabel B, Hankevych T and Schmidt ER: Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene STS) and mouse chromosome 7. Cytogeten Genet Cell Genet 93: 284-290, 2001.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene Ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29, 2000.

Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, et al: Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression. Mol Cancer Ther 14: 2176-2174, 2015.

Hu XG, Chen L, Wang QL, Zhao XL, Tan J, Cui YH, Liu XD, Zhang X and Bian XW: ASCL2 knockdown results in tumor growth arrest by miRNAs-302b-related inhibition of colon cancer proliferation. Plos One 7: e32170, 2012.

Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quipke P, et al: In situ validation of an intestinal stem cell marker in colorectal cancer. Gut 62: 1012-1023, 2013.

Bullard T, Kocke R, Roztocil E, Kingsley PD, Mirleis L and Ovitt CE: ASCL3 expression marks a progenitor population of both acinar and ductal cells in mouse salivary glands. Dev Biol 320: 72-78, 2008.
66. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 15: 5794-5802, 2009.
67. Laflèpide E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506, 2002.
68. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan J,赭 H, Amin MB, Shah RB, and Varambally S: The prognostic and predictive significance of the 8-gene expression score in prostate cancer. J Natl Cancer Inst 93: 1315-1324, 2001.
69. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, et al: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162: 1151-1162, 2003.
70. Yusenkov MV, Kuiper RP, Boethe T, Jiangburg B, van Kessel AG and Kovacs G: High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 9: 152, 2009.
71. Hao Y, Triadafilopoulos G, Sabhaie P, Young HS, Omary MB and Lowe AW: Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology 131: 925-936, 2006.
72. D'Attoma K, Schmauder E, Black MF, Viti F, Falchetti M, Calcagni A, Sera F, Saiava C, Ottini L, Palli D, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 45: 461-469, 2009.
73. Wang Q, Wen YG, Li DP, Xia J, Zhou C, Yan DW, Tang HM and Peng ZH: Unsupervised HNBAs expression is associated with poor survival in gastric cancer. Med Oncol 29: 77-83, 2012.
74. Cui JA, Chen YB, Chou WC, Kong X, Hoffman LL, et al: An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res 39: 1397-1407, 2011.
75. Dyrskjøt L, Kruthoffier M, Thykjaer T, Marcussen N, Jensen JL, Møller K and Ørntoft TF: Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048, 2004.
76. Zhao H, Langerod A, Ju Y, Nowels KW, Nesland JM, Tibshirani R, Bakkum GH, Kåresen R, Botstein D, Børresen-Dale AL and Jeffery SS: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15: 2523-2536, 2004.
77. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Makke C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Sabates-Bellver J, Van der Flier LG, de Palo M, Calcagni A, Sera F, Saiava C, Ottini L, Palli D, et al: Identification of the transcription factor single-minded 1 as a putative marker for ductal invasive breast cancer. J Clin Invest 117: 823-834, 2007.
78. Haqq C, Nos.ptri M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR III, Allen RE, Singer MI, et al: Gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102: 6092-6097, 2005.
79. Ashfaq R, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR III, Allen RE, Singer MI, et al: Gene expression profiling reveals stromal genes associated with tumour progression and metastasis. Bmc Med Genomics 1: 7234-7242, 2008.
80. Dyrskjøt L, Kruthoffier M, Thykjaer T, Marcussen N, Jensen JL, Møller K and Ørntoft TF: Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048, 2004.
81. Zhao H, Langerod A, Ju Y, Nowels KW, Nesland JM, Tibshirani R, Bakkum GH, Kåresen R, Botstein D, Børresen-Dale AL and Jeffery SS: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15: 2523-2536, 2004.
82. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Makke C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Sabates-Bellver J, Van der Flier LG, de Palo M, Calcagni A, Sera F, Saiava C, Ottini L, Palli D, et al: Identification of the transcription factor single-minded 1 as a putative marker for ductal invasive breast cancer. J Clin Invest 117: 823-834, 2007.
83. Haqq C, Nos.ptri M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR III, Allen RE, Singer MI, et al: Gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102: 6092-6097, 2005.
84. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase and SMAD3, in histologically normal mucosa in rectal carcinomas. Genes Chrom Cancer 49: 1024-1034, 2010.
85. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, et al: Transcriptual recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131, 2007.
86. Hong Y, Downey T, Eu KW, Koh PK and Cheah PY: A metastasis-prone signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 27: 83-90, 2010.
87. Skrzypezkz M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 5: e13091, 2010.
88. Hou J, Aerts J, den Haver B, van Ijcken W, den Bakker M, Riegem P, van der Leeest C, van der Spek P, Foecksen JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. Plos One 5: e10312, 2010.
89. Brune V, Tiacici E, Pflüg D, Döring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, van Heydebreck A, Metzler D, et al: Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205: 2251-2268, 2008.
90. Bungo S, den Boon JA, Chen HN, Newton MA, Dahl DB, Chen M, Cheng YJ, Westra WH, Chen CJ, Hildesheim A, et al: Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 66: 7999-8006, 2006.
91. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggery KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300, 2004.
92. Skothem RI, Lind GE, Monnir O, Nesland JM, Abeler VM, Fosså SD, Duane N, Brunborg G, Kallioniemi O, Andrews PW and Lothe RA: Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 65: 5558-5568, 2005.
93. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA and Sanda MG: Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 15: 5794-5802, 2009.
94. Turashvili G, Bouchal J, Baumforth G, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, et al: Gene markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7: 55, 2007.
95. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Felibaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730-5739, 2005.
96. Peyon D, Newton NA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, et al: Differential changes in cell cycle regulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 67: 4605-4619, 2007.
97. Piccaluga PP, Agostinelli C, Calafano A, Rossi M, Basso K, Zupo S, Went P, Klein U, Zinzani PL, Baccarani M, et al: Gene expression analysis of peripheral T cell lymphoma, unspecifed, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117: 823-834, 2007.
98. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337, 2012.